表紙
市場調查報告書

In Silico藥物研發的全球市場:2018-2029年

Global In-Silico Drug Discovery Market: Focus on Products, Technologies, Workflow, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029

出版商 BIS Research Inc. 商品編碼 924766
出版日期 內容資訊 英文 159 Pages
商品交期: 最快1-2個工作天內
價格
In Silico藥物研發的全球市場:2018-2029年 Global In-Silico Drug Discovery Market: Focus on Products, Technologies, Workflow, End Users, Country Data (17 Countries), and Competitive Landscape - Analysis and Forecast, 2018-2029
出版日期: 2020年01月31日內容資訊: 英文 159 Pages
簡介

全球In Silico藥物研發的市場預測將從2018年的20億9450萬美元,在預測期間中以12.92%年複合成長率大幅度成長。對降低醫療錯誤及再住院率的焦點,生物標記鑑定市場成長和In Silico藥物研發技術的進步,計算生物學領域的計算方式技術的進步等要素促進該市場的成長。可是同時,有關技術、次序及醫療治療的應用的高成本,成為進一步成長的障礙。各地區中,北美領導市場,在2018年中記錄了約41.65%的佔有率。該地區在預測期間內也將以大幅度的年複合成長率發展,預計維持其地位。同時,在預測期間內預計記錄最大的年複合成長率的是13.29%的亞太地區。

本報告提供全球In Silico藥物研發的市場調查,市場定義和概要,對市場成長的各種影響因素及市場機會分析,法律規章上架構,競爭環境,各工作流程、產品、軟體類型、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,主要企業簡介等資訊彙整。

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 產業分析

  • 法律規章上架構:各地區

第5章 競爭環境

  • M&A
  • 產品的投入、更新
  • 聯盟、合作
  • 事業擴張、其他
  • 市場佔有率分析

第6章 市場動態

  • 概要
  • 影響分析
  • 成長推動因素
  • 阻礙成長要素
  • 市場機會

第7章 In Silico藥物研發:概要

  • 簡介
  • 市場可用性
  • 技術趨勢

第8章 In Silico藥物研發市場分析、預測:各工作流程

  • 概要
  • 發現
    • 標的鑑定
    • 目標檢驗
    • 領導探索
    • 臨床試驗前
    • 臨床試驗

第9章 In Silico藥物研發市場分析、預測:各產品

  • 軟體
  • SaaS (雲端)
  • CaaS (Consultancy as a Service)

第10章 In Silico藥物研發市場分析、預測:各軟體類型

  • 分子模擬、de Novo藥物設計軟體
  • 藥理學建模軟體

第11章 In Silico藥物研發市場分析、預測:各終端用戶

  • CRO
  • 製藥產業
  • 學術、研究機關
  • 其他 (醫院、其他選擇照護)

第12章 In Silico藥物研發市場分析、預測:各地區、主要國家

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第13章 企業簡介

  • 概要
  • Albany Molecular Research Inc.
  • Certara USA, Inc.
  • Charles River
  • Chemical Computing Group ULC
  • Collaborative Drug Discovery Inc.
  • Dassault System (Biovia)
  • Evotec A.G.
  • GVK Biosciences Private Limited
  • ICAGEN, INC.
  • Novo Informatics Pvt. Ltd.
  • Numerate, Inc.
  • PerkinElmer, Inc.
  • Schrodinger, LLC
  • Selvita
  • Simulation Plus
  • WuXi AppTec
  • e-therapeutics plc
目錄
Product Code: BH180A

"Global In-Silico Drug Discovery Market to Grow at a CAGR of 12.92% from 2019-2029."

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global in-silico drug discovery market?
  • What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?
  • How is each segment of the global in-silico drug discovery market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in the global in-silico drug discovery market? What are the major segments of these applications?
  • Who are the key manufacturers the global in-silico drug discovery market, and what are their contributions?

Global In-Silico Drug Discovery Market Forecast, 2019-2029

The in-silico drug discovery industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.92% during the forecast period, 2019-2029. The in-silico drug discovery market generated $2,094.5 million revenue in 2018, in terms of value. The global in-silico drug discovery market growth has been primarily attributed to the major drivers in this market such as emphasis on reduction in medical errors and readmission rates, growth in the biomarker identification market and advancements in In-silico drug discovery techniques, and computational technological advancements in the field of computational biology. However, there are significant challenges which are restraining the market growth. These challenges include high cost of methods and expensive procedures and their applications in medical treatments.

Expert Quote

"North America is the leading contributor in the in-silico drug discovery market and contributed approximately 41.65% to the global market value in 2018. This region is anticipated to grow at a significant CAGR during the forecast period 2019-2029 and continue dominating the global market in 2029. However, the Asia-Pacific region is expected to grow at the highest CAGR of 13.29% during the forecast period. In addition, the region of Europe also contributed a significant share of 28.40% to the global market in 2018."

Scope of the Market Intelligence on the In-Silico Drug Discovery Market

The in-silico drug discovery research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the service market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global in-silico drug discovery market.

Market Segmentation

The global in-silico drug discovery market segmentation (on the basis of manufacturing and services) is further segmented on the basis of workflow, product, software, end user, and region.

The global in-silico drug discovery market segmentation (on the basis of product) is segmented into software, software as services, and consultancy as a service.

The global in-silico drug discovery market segmentation (on the basis of workflow) is segmented into discovery, pre-clinical tests, and clinical trials.

The global in-silico drug discovery market segmentation (on the basis of software) is segmented into molecular modelling and de novo drug design, and pharmacophore modelling software.

The global in-silico drug discovery market segmentation (on the basis of end user) is segmented into contract research organizations, pharmaceutical industries, and academic and research institutes.

The global in-silico drug discovery market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, Latin America, and rest-of-the-world.

Key Companies in the In-Silico Drug Discovery Market

The key manufacturers who have been contributing significantly to the global in-silico drug discovery market include Albany Molecular Research Inc., Certara USA, Inc., Charles River, Chemical Computing Group ULC, Collaborative Drug Discovery Inc., Dassault System (Biovia) , Evotec A.G., GVK Biosciences Private Limited, ICAGEN, INC., Novo Informatics Pvt. Ltd., Numerate Inc., PerkinElmer Inc, Schrodinger, LLC, Selvita, Simulation Plus, and WuXi AppTec, among others.

Table of Contents

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Research Scope

  • 2.1. Scope of the Study
  • 2.2. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Global In-Silico Drug Discovery Market: Research Methodology
  • 3.2. Primary Data Sources
  • 3.3. Secondary Data Sources
  • 3.4. Market Estimation Model

4. Industry Analysis

  • 4.1. Regulatory Framework
    • 4.1.1. Regulatory Framework in North America
    • 4.1.2. Regulatory Framework in Europe
    • 4.1.3. Regulatory Framework in Asia-Pacific

5. Competitive Landscape

  • 5.1. Mergers and Acquisitions
  • 5.2. Product Launches and Product Updates
  • 5.3. Synergistic Activities
  • 5.4. Business Expansion Activities and Others
  • 5.5. Market Share Analysis

6. Market Dynamics

  • 6.1. Overview
  • 6.2. Impact Analysis
  • 6.3. Market Drivers
    • 6.3.1. Emphasis on Reduction in Medical Errors and Readmission Rates
    • 6.3.2. Growth in the Biomarker Identification Market and Advancements in In-Silico Drug Discovery Techniques
    • 6.3.3. Technological Advancements in the Field of Computational Biology
  • 6.4. Market Restraints
    • 6.4.1. Lack of High Complexity Testing Centers
    • 6.4.2. Expensive Procedures and Their Applications in Medical Treatments
    • 6.4.3. High Capital Requirement Hampering the Expansion of Global Reach
  • 6.5. Market Opportunities
    • 6.5.1. Massive Scope for Adoption of In-Silico drug discovery in Developing Nations
    • 6.5.2. Integration of Blockchain Technology in Interoperability
    • 6.5.3. Collaborations with Precision Medicine Providers

7. In-Silico Drug Discovery: Overview

  • 7.1. Introduction
  • 7.2. Market Availability for In-Silico Drug Discovery
  • 7.3. In-Silico Drug Discovery Market Technology Trends

8. Global In-Silico Drug Discovery Market (by Workflow)

  • 8.1. Overview
  • 8.2. Discovery
    • 8.2.1. Target Identification
      • 8.2.1.1. Bioinformatics
      • 8.2.1.2. Reverse Docking
      • 8.2.1.3. Protein Structure Prediction
    • 8.2.2. Target Validation
    • 8.2.3. Lead Discovery
      • 8.2.3.1. Library Design
      • 8.2.3.2. Pharmacophore
  • 8.3. Pre-Clinical Tests
  • 8.4. Clinical Trials

9. Global In-Silico Drug Discovery Market (by Product)

  • 9.1. Software
  • 9.2. Software as a Service (Cloud)
  • 9.3. Consultancy as a Service

10. Global In-Silico Drug Discovery Market (by Software Type)

  • 10.1. Molecular Modeling and de Novo Drug Design Software
  • 10.2. Pharmacophore Modeling Software

11. Global In-Silico Drug Discovery Market (by End User)

  • 11.1. Contract Research Organizations
  • 11.2. Pharmaceutical Industry
  • 11.3. Academic and Research Institutes
  • 11.4. Other End Users (Hospitals and Other Care Facilities)

12. Global In-Silico Drug Discovery Market, by Region

  • 12.1. Overview
  • 12.2. North America
    • 12.2.1. U.S.
    • 12.2.2. Canada
  • 12.3. Europe
    • 12.3.1. Germany
    • 12.3.2. France
    • 12.3.3. U.K.
    • 12.3.4. Italy
    • 12.3.5. Spain
    • 12.3.6. Russia
    • 12.3.7. Rest-of-Europe
  • 12.4. Asia-Pacific
    • 12.4.1. China
    • 12.4.2. Japan
    • 12.4.3. Australia
    • 12.4.4. India
    • 12.4.5. South Korea
    • 12.4.6. Rest-of-APAC
  • 12.5 Latin America
    • 12.5.1. Brazil
    • 12.5.2. Mexico
  • 12.6 Rest-of-the-World

13. Company Profiles

  • 13.1. Overview
  • 13.2. Albany Molecular Research Inc.
    • 13.2.1. Company Overview
    • 13.2.2. Role of Albany Molecular Research Inc.in the Global In-Silico Drug Discovery Market
    • 13.2.3. SWOT Analysis
  • 13.3. Certara USA, Inc.
    • 13.3.1. Company Overview
    • 13.3.2. Role of Certara USA, Inc. in the Global In-Silico Drug Discovery Market
    • 13.3.3. SWOT Analysis
  • 13.4. Charles River
    • 13.4.1. Company Overview
    • 13.4.2. Role of Charles River in the Global In-Silico Drug Discovery Market
    • 13.4.3. Financials
    • 13.4.4. SWOT Analysis
  • 13.5. Chemical Computing Group ULC
    • 13.5.1. Company Overview
    • 13.5.2. Role of Chemical Computing Group ULC in the Global In-Silico Drug Discovery Market
    • 13.5.3. SWOT Analysis
  • 13.6. Collaborative Drug Discovery Inc.
    • 13.6.1. Company Overview
    • 13.6.2. Role of Collaborative Drug Discovery Inc., in the Global In-Silico Drug Discovery Market
    • 13.6.3. SWOT Analysis
  • 13.7. Dassault System (Biovia)
    • 13.7.1. Company Overview
    • 13.7.2. Role of Dassault System (Biovia) in the Global In-Silico Drug Discovery Market
    • 13.7.3. SWOT Analysis
  • 13.8. Evotec A.G.
    • 13.8.1. Company Overview
    • 13.8.2. Role of Evotec A.G. Company in the Global In-Silico Drug Discovery Market
    • 13.8.3. Financials
    • 13.8.4. Key Insights About Financial Health of the Company
    • 13.8.5. SWOT Analysis
  • 13.9. GVK Biosciences Private Limited
    • 13.9.1. Company Overview
    • 13.9.2. Role of GVK Biosciences Private Limited in the Global In-Silico Drug Discovery Market
    • 13.9.3. SWOT Analysis
  • 13.10 ICAGEN, INC.
    • 13.10.1. Company Overview
    • 13.10.2. Role of ICAGEN, INC. in the Global In-Silico Drug Discovery Market
    • 13.10.3. Financials
    • 13.10.4. Key Insights About Financial Health of the Company
    • 13.10.5. SWOT Analysis
  • 13.11 Novo Informatics Pvt. Ltd.
    • 13.11.1. Company Overview
    • 13.11.2. Role of Novo Informatics Pvt. Ltd. In the Global In-Silico Drug Discovery Market
    • 13.11.3. SWOT Analysis
  • 13.12 Numerate, Inc.
    • 13.12.1. Company Overview
    • 13.12.2. Role of Numerate Inc. in the Global In-Silico Drug Discovery Market
    • 13.12.3. SWOT Analysis
  • 13.13 PerkinElmer, Inc.
    • 13.13.1. Company Overview
    • 13.13.2. Role of PerkinElmer Inc, in Global In-Silico Drug Discovery Market
    • 13.13.3. Financials
    • 13.13.4. Key Insights About Financial Health of the Company
    • 13.13.5. SWOT Analysis
  • 13.14 Schrodinger, LLC
    • 13.14.1. Company Overview
    • 13.14.2. Role of Schrodinger, LLC in the Global In-Silico Drug Discovery Market
    • 13.14.3. SWOT Analysis
  • 13.15 Selvita
    • 13.15.1. Company Overview
    • 13.15.2. Role of Selvita in the Global In-Silico Drug Discovery Market
    • 13.15.3. SWOT Analysis
  • 13.16 Simulation Plus
    • 13.16.1. Company Overview
    • 13.16.2. Role of Simulation Plus in the Global In-Silico Drug Discovery Market
    • 13.16.3. Financials
    • 13.16.4. Key Insights About Financial Health of the Company
    • 13.16.5. SWOT Analysis
  • 13.17 WuXi AppTec
    • 13.17.1. Company Overview
    • 13.17.2. Role of WuXi AppTec in the Global In-Silico Drug Discovery Market
    • 13.17.3. Financials
    • 13.17.4. Key Insights About Financial Health of the Company
    • 13.17.5. SWOT Analysis
  • 13.18 e-therapeutics plc (Snapshot)
    • 13.18.1 Company Overview
    • 13.18.2 Role of e-therapeutics plc in the Global In-Silico Drug Discovery Market
    • 13.18.3 Financials

List of Tables

  • Table 4.1: Regulatory Framework for In-Silico Drug Discovery Market in North America
  • Table 4.2: Regulatory Framework for In-Silico Drug Discovery Market in Europe
  • Table 4.3: Regulatory Framework for In-Silico Drug Discovery Market in Asia-Pacific
  • Table 6.1: Country-Wise Analysis of Adverse Events, 2016

List of Figures

  • Figure 1: Cost Benefit Analysis between Conventional and In-Silico Method
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global In-Silico Drug Discovery Market
  • Figure 3: Global In-Silico Drug Discovery Market, by Workflow, 2018 vs. 2029 ($Million)
  • Figure 4: Global In-Silico Drug Discovery Market, by Product, 2018 vs. 2029 ($Million)
  • Figure 5: Global In-Silico Drug Discovery Market, by Software Type, 2018 vs. 2029 ($Million)
  • Figure 6: Global In-Silico Drug Discovery Market, by End User, 2018 vs. 2029 ($Million)
  • Figure 7: Global In-Silico Drug Discovery Market Snapshot
  • Figure 2.1: Global In-Silico Drug Discovery Market Segmentation
  • Figure 3.1: Global In-Silico Drug Discovery Market Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 5.1: Share of Key Developments and Strategies, January 2016-June 2019
  • Figure 5.2: Product Launches Share (by Company), January 2016-December 2019
  • Figure 5.3: Synergistic Activities Share (by Company), January 2016-December 2019
  • Figure 5.4: Business Expansion Activities Share (by Company), January 2016-December 2019
  • Figure 5.5: Market Share Analysis for the In-Silico Drug Discovery Market, 2018
  • Figure 6.1: Impact Analysis
  • Figure 7.1: Different Steps in the In-Silico Drug Discovery Process
  • Figure 8.1: Global In-Silico Drug Discovery Market (by Workflow)
  • Figure 8.2: Global In-Silico Drug Discovery Market (by Workflow), 2018-2029
  • Figure 8.3: Global In-Silico Drug Discovery Market (Target Identification), 2018-2029
  • Figure 8.4: Global In-Silico Drug Discovery Market (Bioinformatics), 2018-2029
  • Figure 8.5: Global In-Silico Drug Discovery Market (Reverse Docking), 2018-2029
  • Figure 8.6: Global In-Silico Drug Discovery Market (Protein Structure Prediction), 2018-2029
  • Figure 8.7: Global In-Silico Drug Discovery Market (Target Validation), 2018-2029
  • Figure 8.8: Global In-Silico Drug Discovery Market (Lead Discovery), 2018-2029
  • Figure 8.9: Global In-Silico Drug Discovery Market (Library Design), 2018-2029
  • Figure 8.10: Global In-Silico Drug Discovery Market (Pharmacophore), 2018-2029
  • Figure 8.11: Global In-Silico Drug Discovery Market (Pre-Clinical Tests), 2018-2029
  • Figure 8.12: Global In-Silico Drug Discovery Market (Clinical Trials), 2018-2029
  • Figure 9.1: Global In-Silico Drug Market (Software), 2018-2029
  • Figure 9.2: Global In-Silico Drug Market (Software as a Service), 2018-2029
  • Figure 9.3: Global Molecular In-Silico Drug Discovery Market (Consultancy as a Service), 2018-2029
  • Figure 10.1: Global In-Silico Drug Discovery Market (by Molecular Modeling and de Novo Drug Design Software), 2018-2029
  • Figure 10.2: Global In-Silico Drug Market (Pharmacophore Modeling Software), 2018-2029
  • Figure 11.1: Global In-Silico Drug Discovery Market (Contract Research Organizations), 2018-2029
  • Figure 11.2: Global In-Silico Drug Discovery Market (Pharmaceutical Industry), 2018-2029
  • Figure 11.3: Global In-Silico Drug Discovery Market (Academic and Research Institutes), 2018-2029
  • Figure 11.4: Global In-Silico Drug Discovery Market (Hospitals and Other Care Facilities), 2018-2029
  • Figure 12.1: Global In-Silico Drug Discovery Market (by Region)
  • Figure 12.2: Global In-Silico Drug Discovery Market (by Region), 2018-2029
  • Figure 12.3: Global In-Silico Drug Discovery Market Share (by Region), 2018
  • Figure 12.4: Global In-Silico Drug Discovery Market Share (by Region), 2029
  • Figure 12.5: North America In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.6: North America: Market Dynamics
  • Figure 12.7: North America In-Silico Drug Discovery Market (by Country), 2018-2029
  • Figure 12.8: U.S. In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.9: Canada In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.10: Europe In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.11: Europe: Market Dynamics
  • Figure 12.12: Europe In-Silico Drug Discovery Market (by Country), 2018-2029
  • Figure 12.13: Germany In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.14: France In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.15: U.K. In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.16: Italy In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.17: Spain In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.18: Russia In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.19: Rest-of-Europe In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.20: Asia-Pacific In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.21: APAC: Market Dynamics
  • Figure 12.22: APAC In-Silico Drug Discovery Market (by Country), 2018-2029
  • Figure 12.23: China In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.24: Japan In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.25: Australia In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.26: India In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.27: South Korea In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.28: RoAPAC In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.29: Latin America In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.30: Latin America: Market Dynamics
  • Figure 12.31: Latin America In-Silico Drug Discovery Market (by Country), 2018-2029
  • Figure 12.32: Brazil In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.33: Mexico In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.34: Rest-of-Latin America In-Silico Drug Discovery Market, 2018-2029
  • Figure 12.35: RoW In-Silico Drug Discovery Market, 2018-2029
  • Figure 13.1: Total Number of Companies Profiled
  • Figure 13.2: Albany Molecular Research Inc.: Product Portfolio
  • Figure 13.3: Albany Molecular Research Inc.: SWOT Analysis
  • Figure 13.4: Certara USA, Inc.: Product Portfolio
  • Figure 13.5: Certara USA, Inc.: SWOT Analysis
  • Figure 13.6: Charles River: Overall Financials, 2016-2018
  • Figure 13.7: Charles River: Revenue (by Segment), 2016-2018
  • Figure 13.8: Charles River: SWOT Analysis
  • Figure 13.9: Chemical Computing Group ULC: Product Portfolio
  • Figure 13.10: Chemical Computing Group: SWOT Analysis
  • Figure 13.11: Collaborative Drug Discovery Inc.: Overall Product Portfolio
  • Figure 13.12: Collaborative Drug Discovery Inc.: SWOT Analysis
  • Figure 13.13: Dassault Systems (Biovia): Product Offerings
  • Figure 13.14: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 13.15: Evotec A.G. Company: Overall Financials, 2016-2018
  • Figure 13.16: Evotec A.G.: R&D Expenditure, 2016-2018
  • Figure 13.17: Evotec A.G. Company: SWOT Analysis
  • Figure 13.18: Product Portfolio: GVK Biosciences Private Limited
  • Figure 13.19: GVK Biosciences Private Limited SE.: SWOT Analysis
  • Figure 13.20: ICAGEN, INC.: Overall Product Portfolio
  • Figure 13.21: ICAGEN, INC.: Overall Financials, 2016-2018
  • Figure 13.22: ICAGEN, INC.: R&D Expenditure, 2016-2018
  • Figure 13.23: ICAGEN, INC.: SWOT Analysis
  • Figure 13.24: GE Healthcare: Product Portfolio
  • Figure 13.25: Novo Informatics Pvt. Ltd. Company: SWOT Analysis
  • Figure 13.26: Numerate Inc.: Overall Product Portfolio
  • Figure 13.27: Numerate Inc.: SWOT Analysis
  • Figure 13.28: PerkinElmer, Inc.: Product Portfolio for Global In-Silico Drug Discovery Market
  • Figure 13.29: PerkinElmer, Inc.: Overall Financials, 2016-2018
  • Figure 13.30: PerkinElmer, Inc.: Revenue (by Segment), 2016-2018
  • Figure 13.31: PerkinElmer, Inc.: Revenue (by Region), 2016-2017
  • Figure 13.32: PerkinElmer, Inc.: Revenue (by Region), 2018
  • Figure 13.33: PerkinElmer, Inc.: R&D Expenditure ,2016-2018
  • Figure 13.34: PerkinElmer, Inc.: SWOT Analysis
  • Figure 13.35: Schrodinger, LLC: SWOT Analysis
  • Figure 13.36: Selvita: Product Portfolio
  • Figure 13.37: Selvita: SWOT Analysis
  • Figure 13.38: Simulation Plus: Product Portfolio
  • Figure 13.39: Simulation Plus.: Overall Financials, 2017-2019
  • Figure 13.40: Simulation Plus: Revenue (by Region), 2017-2019
  • Figure 13.41: Simulation Plus: R&D Expenditure, 2016-2018
  • Figure 13.42: Simulation Plus: SWOT Analysis
  • Figure 13.43: WuXi AppTec.: Overall Financials, 2017-2019
  • Figure 13.44: WuXi AppTec: R&D Expenditure, 2016-2018
  • Figure 13.45: WuXi AppTec: SWOT Analysis
  • Figure 13.46: e-therapeutics plc: Product Portfolio
  • Figure 13.47: e-therapeutics plc: Overall Financials, 2017-2019